Alzheimer's disease

López, José Arguedas; González, Hector M.; Léger, Gabriel C.

doi:10.1016/b978-0-12-804766-8.00013-3

Cited by 546 publications

(404 citation statements)

References 237 publications

Supporting

Mentioning

324

Contrasting

Unclassified

Order By: Relevance

“…Rho GTPases, as well as their regulators and effector molecules, play an important role in neurodegenerative processes, such as regulating APP processing or dendritic spine loss in AD [ 17 ] and oxidative stress and neuroinflammation in PD [ 18 , 74 ]. Furthermore, Rho GTPases are also implicated in other diseases related to the nervous system [ 12 ]. For instance, they are involved in amyotrophic lateral sclerosis (ALS) by regulating motor neuron survival and they control Huntingtin protein accumulation in Huntington’s disease [ 12 ].…”

Section: Small Gtpases Of the Rho Familymentioning

confidence: 99%

“…Furthermore, Rho GTPases are also implicated in other diseases related to the nervous system [ 12 ]. For instance, they are involved in amyotrophic lateral sclerosis (ALS) by regulating motor neuron survival and they control Huntingtin protein accumulation in Huntington’s disease [ 12 ].…”

Section: Small Gtpases Of the Rho Familymentioning

confidence: 99%

“…Together with Ras and Rho, Rac is considered a protooncogene, and mutations in these GTPases confer them a constitutive activity in various types of tumors [ 11 ]. Apart from participating in tumoral processes, Rac1 plays a key role in development and neuronal survival as well as in neurodegeneration [ 12 ].…”

Section: Small Gtpases Of the Rho Familymentioning

confidence: 99%

“…The most common form of dementia, AD, is a progressive and irreversible neurodegenerative disorder [ 12 ]. It is characterized by the abnormal accumulation of both Tau protein and Aβ peptides.…”

Section: Introductionmentioning

confidence: 99%

“…The accumulation and spreading of Aβ peptides (called senile plaques) are also a hallmark of AD. The accumulation and aggregation of both proteins induce the degeneration of hippocampal and cerebral cortex neurons, resulting in the typical AD symptoms that include memory loss, spatiotemporal disorientation, or behavioral changes among others [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases

Sastre

Montoro

Gálvez‐Martín

et al. 2020

IJMS

View full text Add to dashboard Cite

Small guanosine triphosphatases (GTPases) of the Ras superfamily are key regulators of many key cellular events such as proliferation, differentiation, cell cycle regulation, migration, or apoptosis. To control these biological responses, GTPases activity is regulated by guanine nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs), and in some small GTPases also guanine nucleotide dissociation inhibitors (GDIs). Moreover, small GTPases transduce signals by their downstream effector molecules. Many studies demonstrate that small GTPases of the Ras family are involved in neurodegeneration processes. Here, in this review, we focus on the signaling pathways controlled by these small protein superfamilies that culminate in neurodegenerative pathologies, such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). Specifically, we concentrate on the two most studied families of the Ras superfamily: the Ras and Rho families. We summarize the latest findings of small GTPases of the Ras and Rho families in neurodegeneration in order to highlight these small proteins as potential therapeutic targets capable of slowing down different neurodegenerative diseases.

show abstract

Section: Small Gtpases Of the Rho Familymentioning

confidence: 99%

Section: Small Gtpases Of the Rho Familymentioning

confidence: 99%

Section: Small Gtpases Of the Rho Familymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases

Sastre

Montoro

Gálvez‐Martín

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

Ocular Biomarkers for Alzheimer Disease Dementia

et al. 2023

View full text Add to dashboard Cite

ImportanceSeveral ocular biomarkers have been proposed for the early detection of Alzheimer disease (AD) and mild cognitive impairment (MCI), particularly fundus photography, optical coherence tomography (OCT), and OCT angiography (OCTA).ObjectiveTo perform an umbrella review of systematic reviews to assess the diagnostic accuracy of ocular biomarkers for early diagnosis of Alzheimer disease.Data SourcesMEDLINE, Embase, and PsycINFO were searched from January 2000 to November 2021. The references of included reviews were also searched.Study SelectionSystematic reviews investigating the diagnostic accuracy of ocular biomarkers to detect AD and MCI, in secondary care or memory clinics, against established clinical criteria or clinical judgment.Data Extraction and SynthesisThe Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline checklist was followed and the Risk Of Bias in Systematic reviews tool was used to assess review quality.Main Outcomes and MeasuresThe prespecified outcome was the accuracy of ocular biomarkers for diagnosing AD and MCI. The area under the curve (AUC) was derived from standardized mean difference.ResultsFrom the 591 titles, 14 systematic reviews were included (median [range] number of studies in each review, 14 [5-126]). Only 4 reviews were at low risk of bias on all Risk of Bias in Systematic Reviews domains. The imaging-derived parameters with the most evidence for detecting AD compared with healthy controls were OCT peripapillary retinal nerve fiber layer thickness (38 studies including 1883 patients with AD and 2510 controls; AUC = 0.70; 95% CI, 0.53-0.79); OCTA foveal avascular zone (5 studies including 177 patients with AD and 371 controls; AUC = 0.73; 95% CI, 0.50-0.89); and saccadic eye movements prosaccade latency (30 studies including 651 patients with AD/MCI and 771 controls; AUC = 0.64; 95% CI, 0.58-0.69). Antisaccade error was investigated in fewer studies (12 studies including 424 patients with AD/MCI and 382 controls) and yielded the best accuracy (AUC = 0.79; 95% CI, 0.70-0.88).Conclusions and RelevanceThis umbrella review has highlighted limitations in design and reporting of the existing research on ocular biomarkers for diagnosing AD. Parameters with the best evidence showed poor to moderate diagnostic accuracy in cross-sectional studies. Future longitudinal studies should investigate whether changes in OCT and OCTA measurements over time can yield accurate predictions of AD onset.

show abstract

Peptide‐Based Supramolecular Therapeutics for Fighting Major Diseases

Wang,

Luo,

Wang

et al. 2024

Adv Funct Materials

View full text Add to dashboard Cite

Peptide‐based supramolecular therapeutics (PST) refer to those theranostic nanomedicines based on peptide or peptide derivatives self‐assembly that are constructed in vitro or in vivo. Benefiting from the inherent advantages of peptides, such as good biocompatibility, high bioactivity, and flexible tunability, the reported PST have shown excellent application prospects in combating many major diseases including cancer, cardiovascular disease, infectious disease, autoimmune disease, metabolic disease, and so on. Through thoughtful design, the PST can be fabricated in various forms, including self‐assembled precursor molecules, functional nano‐assemblies, and macroscopic large‐scale hydrogels. The involved peptides in the PST can play different roles, such as serving drug carriers for effective delivery, acting as scaffold materials for cell culture, and functioning as bioactive sequences for treating diseases. In this review, a comprehensive overview of traditional strategies is provided to build PST and emphasize their therapeutic applications for fighting major diseases that pose a threat to human life and health. Moreover, the main challenges of PST in systems design, therapeutic application, and clinical translation are also briefly discussed. It is hoped that this review can arouse much more attention to be paid for PST and promote its practical application in the biomedical field.

show abstract

Alzheimer's disease

Cited by 546 publications

References 237 publications

Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases

Small GTPases of the Ras and Rho Families Switch on/off Signaling Pathways in Neurodegenerative Diseases

Ocular Biomarkers for Alzheimer Disease Dementia

Peptide‐Based Supramolecular Therapeutics for Fighting Major Diseases

Contact Info

Product

Resources

About